Showing results (131-140 of 144) with videos related to
Sort By:
Pageof 15
Transplantation and Cellular Therapy|April 11, 2021
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group ReportCarrie L Kitko, Joseph Pidala, Hélène M Schoemans, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 7, 2018
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free SurvivalAmin Alousi, Tao Wang, Michael T Hemmer, et al.Transplantation and Cellular Therapy|November 25, 2022
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation SurvivorsSanghee Hong, Jing Zhao, Shu Wang, et al.Science Translational Medicine|November 26, 2020
Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantationLam T Khuat, Catherine T Le, Chien-Chun Steven Pai, et al.Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.Blood Advances|August 9, 2018
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, et al.The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.Pageof 15